Department of Defense Awards Emergent BioSolutions With $235.8 Million Contract for Anthrax Vaccine

Posted on by admin

The BioThrax vaccine is indicated for active immunization to prevent anthrax disease caused by Bacillus anthracis in individuals aged 18 through 65 years.

Leave a Reply

Your email address will not be published. Required fields are marked *